Expression of p53 in cisplatin-resistant ovarian cancer cell lines: Modulation with the novel platinum analogue (1R, 2R- diaminocyclohexane)(trans-diacetato)(dichloro)platinum(IV)

Clinical Cancer Research

Volumn 5, Issue 3, 1999, Pages 655-663

  Hagopian, George S ^a   Mills, Gordon B ^a   Khokhar, Abdul R ^a   Bast Jr , Robert C ^a   Siddik, Zahid H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DIAMINOCYCLOHEXANE DIACETATO DICHLOROPLATINUM IV; PLATINUM DERIVATIVE; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CLONING; CELL CYCLE; CELL MUTANT; CYTOTOXICITY; DRUG EXPOSURE; DRUG STRUCTURE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NULL CELL; OVARY CANCER; PLASMID; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; WART VIRUS;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL SURVIVAL; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG RESISTANCE, NEOPLASM; FEMALE; G1 PHASE; HUMANS; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033037410     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1997. CA Cancer J. Clin., 47: 5-27, 1997.
2. Thigpen, T., Vance, R., Khansur, T., and Malamud, F. The role of chemotherapy in the management of celomic epithelial carcinoma of the ovary. Cancer Invest., 15: 277-287, 1997.
3. Steele, G. D., Jr., Osteen, R. T., Winchester, D. P., Murphy, G. P., and Menck, H. R. Clinical highlights from the National Cancer Data Base: 1994. CA Cancer J. Clin., 44: 71-80, 1994.
4. Ozols, R. F. Ovarian cancer. Semin. Surg. Oncol., 6, 328-338, 1990.
5. Benjamin, I., and Rubin, S. C. Initial surgical management of advanced epithelial ovarian cancer. Cancer Invest., 15: 270-276, 1997.
6. McGuire, W. P., Hoskins, W. J., Brady, M. P., Kucera, P. R., Partridge, E. F., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med., 334: 1-6, 1996.
7. Runowicz, C. D. Advances in the screening and treatment of ovarian cancer. CA Cancer J. Clin., 42: 327-349, 1992.
8. Kido, Y. Khokhar, A. R., Al-Baker, S., and Siddik, Z. H. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum(IV) complexes mediated by axial and equatorial ligands. Cancer Res., 53: 4567-4572, 1993.
9. 2 phase checkpoints. In: M. Kastan (ed.), Cancer Surveys, Vol. 29: Checkpoint Controls and Cancer, pp. 151-182. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1997.
10. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Jr., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54: 5824-5830, 1994.
11. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C. Hooper, M. L., and Wyllie, A. H. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
12. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
13. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. Thymocyte apoptosis induced by p53-dependent and -independent pathways. Nature (Lond.), 362: 849-852, 1993.
14. Radford, I. R., Murphy, J. M., Radley, J. M., and Ellis, S. L. Radiation response of mouse lymphoid and myeloid cell lines. Part II. Apoptotic death is shown by all lines examined. Int. J. Radiat. Biol., 65: 217-227, 1994.
15. O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776-4780, 1993.
16. Lee, J. M., and Bernstein, A. p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA, 90: 5742-5746, 1993.
17. McIlwrath, A. J., Vasey, P. A., Ross, G. M., and Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res., 54: 3718-3722, 1994.
18. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53: 4164-4168, 1993.
19. Brachman, D. G., Beckett, M. Graves, D., Haraf, D., Vokes, E., and Weichselbaum, R. R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res., 53: 3667-3669, 1993.
20. Righetti, S. C., Torre, G. D., Pilotti, S., Menard, S., Ottone, F., Colnaghi, M. I., Pierotti, M. A., Lavarino, C., Cornarotti, M., Oriana, S., Bohm, S., Bresciani, G. L., Spatti, G., and Zunino, F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res., 56: 689-693, 1996.
21. Fan, S., Smith, M. L., Rivet, D. J., Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., Jr., and O'Connor, P. M. Disruption of p53 sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
22. Hawkins, D. S., Demers, G. W., and Galloway, D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56: 892-898, 1996.
23. Vollano, J. F., Al-Baker, S., Dabrowiak, J. C., and Schurig, J. E. Comparative anti-tumor studies on platinum(II) and platinum(IV) complexes containing 1,2-diaminocyclohexane. J. Med. Chem., 30: 716-719, 1987.
24. Al-Baker, S., Siddik, Z. H., and Khokhar, A. R. Synthesis and characterization of new antitumor trans-R,R-, trans-S,S-, and cis-1,2-diaminocyclohexane platinum(IV) complexes. J. Coord. Chem., 31: 109-116, 1994.
25. Siddik, Z. H., Boxall, F. E., and Harrap, K. R. Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Anal. Biochem., 163: 21-26, 1987.
26. Bast, R. C., Jr., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., and Knapp, R. C. Reactivity of a monoclonal antibody with human ovarian carcinomas. J. Clin. Invest., 68: 1331-1337, 1981.
27. Xu, Y., Gaudette, D. C., Boynton, J. D., Frankel, A., Fang, X-J., Sharma, A., Hurteau, J., Casey, G., Goodbody, A., Mellors, A., Holub, B. J., and Mills, G. B. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin. Cancer Res., I: 1223-1232, 1995.
28. Perez, R. P., O'Dwyer, P. J., Handel, L. M., Ozols, R. F., and Hamilton, T. C. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines. Int. J. Cancer. 48: 265-269, 1991.
29. Kelland, L. R., and Abel, G. Comparative in vitro cytotoxicity of Taxol and taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol., 30: 444-450, 1992.
30. Buick, R. N., Pullano, R., and Trent, J. M. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res., 45: 3668-3676, 1985.
31. Elbendary, A., Berchuck, A., Davis, P., Havrilesky, L., Bast, Jr., R. C., Iglehart, J. D., and Marks, J. R. Transforming growth factor β1 can induce cip1/waf1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ., 5: 1301-1307, 1994.
32. Wolf, J. K., Bazelle, L., Mills, G. B., Bast, R. C., Roth, J. A., and Gershenson, D. M. Growth inhibition of human ovarian cancer cells by transfection with adenovirus-mediated p53 is independent of endogenous p53 status. Proc. Am. Assoc. Cancer Res., 37: 205, 1996.
33. Yaginuma, Y., and Westphal, H. Abnormal structure and expression of p53 gene in human ovarian carcinoma cell lines. Cancer Res., 52: 4196-4199, 1992.
34. Kessis, T. D., Slebos, R. J., Nelson W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., Lorincz, A. T., Hedrick, L., and Cho, K. R. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA, 90: 3988-3992, 1993.
35. Scheffner, M., Huibregtse, J. M., and Howley, P. M. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of. p53. Proc. Natl. Acad. Sci. USA, 91: 8797-8801, 1994.
36. Carmichael, J., Degraff, W., Gazdar, A., Minna, J., and Mitchell, J. Evaluation of a tetrazolium-based semi-automatic colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47: 936-942, 1987.
37. Kido, Y, Khokhar, A. R., and Siddik Z. H. Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cells. Anti-Cancer Drugs, 4: 251-258, 1993.
38. Rosenberg, B., Van Camp, L., and Krigas, T. Letter: inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature (Lond.), 205: 698-699, 1965.
39. Rosenberg, B., Van Camp, L., Trosco, J. E., and Mansour, V. H. Platinum compounds: a new class of potent antitumor agents. Nature (Lond.), 222: 385-386, 1969.
40. Kelland, L. R. Prospects for improved cisplatin analogs. In: F. Sharp, T. Blackett, R. Leake, and J. Berek (eds.), Ovarian Cancer, Vol. 4, pp. 249-258. London: Chapman and Hall, 1996.
41. Ruley, H. E. p53 and response to chemotherapy and radiotherapy. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Important Advances in Oncology, pp. 37-56. Philadelphia: Lippincott-Raven Publishers, 1996.
42. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
43. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
44. Hartwell, L. H., and Kastan, M. B. Cell cycle control and cancer. Science (Washington DC), 266: 1821-1828, 1994.
45. Scheffner, M., Werness, B. A., Huilbregtse, J. M., Levine, A. J., and Howley, P. M. The E6 oncoprotein encoded by the human papilloma-virus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990.
46. Artuso, M., Esteve, A., Bresil, H., Vuillaume, M., and Hall, J. The role of the ataxia-telangiectasia gene in the p53-, waf1/cip1 (p21)- and GADD45-mediated response to DNA damage produced by ionizing radiation. Oncogene, 11: 1427-1435, 1995.
47. Zhang, N., Song, Q., Lu, H., and Lavin, M. F. Induction of p53 and increased sensitivity to cisplatin in ataxia-telangiectasia cells. Oncogene, 13: 655-659, 1996.
48. Siddik, Z. H., Minis, B., Lozano, G., and Thai, G. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res., 58: 698-703, 1998.
49. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
50. 1 arrest in human cancer cells. Cancer Res., 55: 5187-5190, 1995.
51. Onmerod, M. G., Orr, R. M., and Peacock, J. H. The role of apoptosis in cell killing by cisplatin: a flow cytometric study. Br. J. Cancer, 69: 93-100, 1994.
52. 2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst. (Bethesda). 82: 749-755, 1990.
53. 2 arrest and DNA double strand breaks. Cancer Res., 48: 4484-4488, 1988.
54. Demarcq, C., Bunch, R. T., Creswell, D., and Eastman, A. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ., 5: 983-993, 1994.
55. 1 checkpoint control. Cell. 82: 675-684, 1995.
56. Attardi, L. D., Lowe, S. W., Brugarolas, J., and Jacks, T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J., 15: 3693-3701, 1996.
57. Pinto, A. L., and Lippard, S. J. Binding of the antitumor drug cis-diamminedichloro-platinum(II) (cisplatin) to DNA. Biochim. Biophys. Acta. 780: 167-180, 1985.
58. Roberts, J. J., and Friedlos, F. Quantitative estimations of cis-platin-induced DNA interstrand cross-links and their repair in mammalian cells: relationship to toxicity. Pharmacol. Ther., 34: 215-246, 1987.
59. Ries, L. A. G., Kosary, C. L., Hankey, B. F., Miller, B. A., and Edwards, B. K. (eds.). SEER Cancer Statistics Review, 1973-1993. Tables and Graphs. Bethesda: National Cancer Institute, 1996.